Massive Bio Earns DiMe Seal and Joins the CMS Medicare App Library
What this means for cancer patients, healthcare providers, and the future of clinical trial access
At Massive Bio, we have always believed that connecting cancer patients to the right clinical trials requires more than technology. It requires trust. Today, we are proud to share two milestones that reflect our commitment to building that trust at the highest institutional level.
Massive Bio has earned the DiMe Seal, issued by the Digital Medicine Society, and as a direct result, is now listed in the CMS Medicare App Library.
What Is the DiMe Seal?
The DiMe Seal is an independent, evidence-based quality certification issued by the Digital Medicine Society, a global non-profit dedicated to the ethical and effective use of digital medicine. It is not a self-reported badge. It is earned through a rigorous evaluation process that assesses digital health applications across four critical pillars: clinical evidence, privacy and security, usability, and interoperability.
For Massive Bio, earning the DiMe Seal means that an independent, expert body has reviewed our platform and confirmed that it meets the highest standards for patient-facing digital health technology.
What Is the CMS Medicare App Library?
The CMS Medicare App Library is a federal marketplace of vetted digital health applications, built and operated by the Centers for Medicare and Medicaid Services. It is designed to give the more than 68 million Medicare beneficiaries in the United States access to trusted, high-quality digital health tools that integrate directly with CMS infrastructure.
Inclusion in the library is not open to all. As of February 2026, CMS designated the DiMe Seal as the required credential for any application seeking entry. In other words, the DiMe Seal is the gateway, and the CMS Medicare App Library is the destination.
Why This Matters for Cancer Patients
Cancer patients navigating a diagnosis face enormous complexity. Finding the right clinical trial, understanding eligibility, and connecting with the right care team can feel overwhelming. Massive Bio exists to simplify that journey.
Being listed in the CMS Medicare App Library means that Medicare beneficiaries, millions of whom are cancer patients or caregivers, can discover and access Massive Bio through a federally recognized, trusted channel. The DiMe Seal assures them that the platform they are using has been independently verified for safety, evidence, and usability.
Why This Matters for Healthcare Providers and Partners
For oncologists, hospital systems, pharmaceutical companies, and clinical trial sponsors, these credentials carry significant weight. They signal that Massive Bio operates to a standard that has been recognized by both an independent scientific body and the federal government.
This makes the conversation around partnership, data sharing, and patient referral significantly simpler. The vetting has already been done, by parties that both sides trust.
A Foundation for What Comes Next
Massive Bio operates across 17 countries, supports clinical trial access for patients with more than 100 cancer types, and continues to expand its AI-driven platform with solutions like NexusPulse and TrialRelay. As a founding member of the CancerX public-private partnership and a participant in the White House Cancer Moonshot initiative, we are committed to building infrastructure that the entire oncology ecosystem can rely on.
The DiMe Seal and CMS Medicare App Library listing are not the finish line. They are a foundation, one that reflects where we have been and supports everything we are building next.
